Q-omics provides the consensus-scored AKR7A3 profile across patient tissues and cancer cell-line models. AKR7A3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AKR7A3 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, AKR7A3 RNA expression shows 19,492 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, KIRP, and BRCA as cancer lineages where AKR7A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR7A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR7A3 survival associations across molecular data types. AKR7A3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR7A3 RNA expression–survival associations across cancer types. High AKR7A3 expression shows unfavorable associations in UVM, ACC and LGG, but favorable associations in KIRC, KIRP and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AKR7A3 RNA expression.
This table summarizes AKR7A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AKR7A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR7A3 shows lower tumor expression in KIRP, THCA, LIHC and KIRC and higher tumor expression in LUAD and LUSC. The KIRP box plot shows higher AKR7A3 RNA expression in normal versus tumor tissue (log2 FC = −3.084, t-test p < 0.001).
This table shows molecular features associated with AKR7A3 in patient tissues and cancer cell lines. In patient samples, AKR7A3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, AKR7A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
